276 related articles for article (PubMed ID: 36220487)
1. Nanomedicine for advanced cancer immunotherapy.
Diep YN; Kim TJ; Cho H; Lee LP
J Control Release; 2022 Nov; 351():1017-1037. PubMed ID: 36220487
[TBL] [Abstract][Full Text] [Related]
2. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
3. The viral approach to breast cancer immunotherapy.
Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
[TBL] [Abstract][Full Text] [Related]
4. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors.
Park AK; Fong Y; Kim SI; Yang J; Murad JP; Lu J; Jeang B; Chang WC; Chen NG; Thomas SH; Forman SJ; Priceman SJ
Sci Transl Med; 2020 Sep; 12(559):. PubMed ID: 32878978
[TBL] [Abstract][Full Text] [Related]
5. Going viral with cancer immunotherapy.
Lichty BD; Breitbach CJ; Stojdl DF; Bell JC
Nat Rev Cancer; 2014 Aug; 14(8):559-67. PubMed ID: 24990523
[TBL] [Abstract][Full Text] [Related]
6. Virus-inspired strategies for cancer therapy.
Ma XY; Hill BD; Hoang T; Wen F
Semin Cancer Biol; 2022 Nov; 86(Pt 3):1143-1157. PubMed ID: 34182141
[TBL] [Abstract][Full Text] [Related]
7. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
8. Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer.
Jin X; Liu Z; Yang D; Yin K; Chang X
Front Immunol; 2022; 13():948647. PubMed ID: 35844558
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment.
Rosewell Shaw A; Suzuki M
Front Immunol; 2018; 9():2103. PubMed ID: 30298067
[TBL] [Abstract][Full Text] [Related]
10. Vaccine-like nanomedicine for cancer immunotherapy.
Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
12. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
Crupi MJF; Bell JC; Singaravelu R
Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.
McKenna MK; Englisch A; Brenner B; Smith T; Hoyos V; Suzuki M; Brenner MK
Mol Ther; 2021 May; 29(5):1808-1820. PubMed ID: 33571680
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of glioblastoma: Recent advances and future prospects.
Yuan B; Wang G; Tang X; Tong A; Zhou L
Hum Vaccin Immunother; 2022 Nov; 18(5):2055417. PubMed ID: 35344682
[TBL] [Abstract][Full Text] [Related]
16. Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects.
Chen J; Cong X
Biomed Pharmacother; 2023 Jan; 157():113998. PubMed ID: 36399829
[TBL] [Abstract][Full Text] [Related]
17. Polymeric Systems for Cancer Immunotherapy: A Review.
Le TMD; Yoon AR; Thambi T; Yun CO
Front Immunol; 2022; 13():826876. PubMed ID: 35273607
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy: an alternative promising therapeutic approach against cancers.
Gupta SL; Basu S; Soni V; Jaiswal RK
Mol Biol Rep; 2022 Oct; 49(10):9903-9913. PubMed ID: 35759082
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated specific tumor tagging facilitates CAR-T therapy against antigen-mismatched solid tumors.
Tang X; Li Y; Ma J; Wang X; Zhao W; Hossain MA; Yang Y
Cancer Lett; 2020 Sep; 487():1-9. PubMed ID: 32454143
[TBL] [Abstract][Full Text] [Related]
20. Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy.
Shang Q; Dong Y; Su Y; Leslie F; Sun M; Wang F
Adv Drug Deliv Rev; 2022 Jun; 185():114308. PubMed ID: 35472398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
